Type 2 Diabetes

A monocentric randomized crossover study of 16 subjects provides insight into the difference in glycemic control, device acceptance, and psychological outcomes based on use of implantable versus transcutaneous.

Results of a systematic review and meta-analysis detail the reduction in fear of hypoglycemia and general improvement in satisfaction associated with use of continuous glucose monitoring in patients with type 1 diabetes.

A meta-analysis including 11 studies with nearly 14k patients is providing insight into associations between time in range and risk of microvascular complications in patients with type 2 diabetes.

Data from the MOBILE study detail the potential impact of continuous glucose monitoring on HbA1c level compared with blood glucose meter monitoring in a population of patients with type 2 diabetes treated with basal insulin without prandial insulin.

A cross-sectional study of 83 patients with diabetes of the exocrine pancreas provides insight into the potential benefits of continuous glucose monitoring among these patients.

A meta-analysis of observational studies provides clinicians with a comprehensive overview of the impact of lockdown measures during the COVID-19 pandemic on glucose control in patients with type 1 diabetes.

New research from the University of Virginia Health System describes factors associated with increased arterial stiffness from a cohort of adolescents and young adults with type 1 diabetes.

A comparison of data and care from prepandemic and pandemic periods provides an overview of the impact deferred care and stay-at-home orders on the rate of amputations and other outcomes among patients with diabetes.

With the aim of improving the rate of patients with diabetes achieving optimized cardiovascular risk factor management, the AHA has released a scientific statement detailing contemporary data and management approaches to help achieve these goals.

Released on Jan. 10, the latest scientific statement from the American Heart Association details gaps in cardiovascular risk management impacting the majority of patients with type 2 diabetes within the US.

Results of a recent study detail a significant link between incidence of diabetes and chronic rhinosinusitis with nasal polyps that was not observed for CRS without nasal polyps was not associated with diabetes.

A recent analysis found patients with benign adrenal tumors and MACS were at an increased risk of cardiometabolic diseases.

A cross-sectional study of more than 1000 patients suggests presence of MACS in patients with benign adrenal tumors was associated with increased prevalence and severity of hypertension as well as an increase in the likelihood of requiring insulin therapy in type 2 diabetes.

The estimated prevalence of diabetes increased from 10.9% in 2013 to 12.4% in 2018, without a significant improvement seen in adequate treatment.

An analysis of data from more than 1.1 million patients provides an overview of inequities in use of GLP-1 RAs among patients with diabetes based on racial/ethnic background and household income.

The American Academy of Neurology released guidelines detailing oral and topical treatment options for management of painful diabetic neuropathy on December 27.

Data show Asian, Black, and Hispanic patients and those with lower income were less likely to receive treatment with GLP-1 RAs.

The latest endocrine case report from Brady Pregerson, MD, features a man in his 60s with diabetes and left below-knee amputation for a smelly right foot that has been getting gradually worse for 2 weeks. Check out the report, labs, and imaging and see if you can determine the correct diagnosis.

Dr. Shapiro discusses the implantable VC-02 device success in producing C-peptide in patients with type 1 diabetes and what is coming next.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, FDA news, and more.

Each month, our editorial staff compiles a month in review highlighting the most popular content from the past month. December's month in review features new guidelines, stories on the effect of delayed visits, and more.

A high-potential drug for type 1 diabetes may not have received regulation this year, but it sparked vital conversation among experts.

A trial comparing changes in blood glucose before, during, and after exercise at sea level and simulated altitude provides insight into the potential increase in risk for hypoglycemia among patients with type 1 diabetes.

Dr. Jellinger discusses the lipid section of the DCRM guidelines, the role of combination therapies in lowering LDL and what is coming next for the field of diabetes in 2022.